Dr Emma Lane
Senior Lecturer
Ysgol Fferylliaeth a Gwyddorau Fferyllol
- Sylwebydd y cyfryngau
- Ar gael fel goruchwyliwr ôl-raddedig
Trosolwyg
Qualifications
- B.Sc. in Pharmacology, University College London, 2000
- Ph.D. in Neuropharmacology, King's College London, 2004
Relevant websites
- Brain Repair Group with the School of Biosciences
- NECTAR (Network of European CNS Transplantation and Restoration)
- STEMnet, STEM ambassador
- Cardiff University Neuroscience News
Funding bodies which support my work
Cyhoeddiad
2023
- Lambourne, O. A. et al. 2023. PINK1-Dependent mitophagy inhibits elevated ubiquitin phosphorylation caused by mitochondrial damage. Journal of Medicinal Chemistry 66(11), pp. 7645-7656. (10.1021/acs.jmedchem.3c00555)
2022
- Lane, E. L., Isaacs, L. and Mathur, S. 2022. More than a participant in trials of cell and gene therapy: Hearing the voices of people living with neurodegenerative diseases. In: International Review of Neurobiology., Vol. 166. ELSEVIER ACADEMIC PRESS INC, pp. 281-312., (10.1016/bs.irn.2022.09.007)
- Lane, E. L. and Lelos, M. J. 2022. Defining the unknowns for cell therapies in Parkinson's disease. Disease Models and Mechanisms 15(10), article number: dmm049543. (10.1242/dmm.049543)
- Elabi, O. F. et al. 2022. Human embryonic stem cell-derived dopaminergic grafts alleviate L-DOPA induced dyskinesia. Journal of Parkinson's Disease 12(6), pp. 1881-1896. (10.3233/JPD-212920)
- Lane, E. L., Harrison, D. J., Ramos-Varas, E., Hills, R., Turner, S. and Lelos, M. J. 2022. Spontaneous graft-induced dyskinesias are independent of 5-HT neurons and levodopa priming in a model of Parkinson's disease. Movement Disorders 37(3), pp. 613-619. (10.1002/mds.28856)
2021
- Elabi, O. F., Davies, J. S. and Lane, E. L. 2021. L-dopa-dependent effects of GLP-1R agonists on the survival of dopaminergic cells transplanted into a rat model of Parkinson disease. International Journal of Molecular Sciences 22(22), article number: 12346. (10.3390/ijms222212346)
- Orayj, K., Akbari, A., Lacey, A., Smith, M., Pickrell, O. and Lane, E. L. 2021. Factors affecting the choice of first-line therapy in Parkinson's disease patients in Wales: A population-based study. Saudi Pharmaceutical Journal 29(2), pp. 206-212. (10.1016/j.jsps.2021.01.004)
2020
- Precious, S. V. et al. 2020. Dopaminergic progenitors derived from epiblast stem cells function similarly to primary VM-derived progenitors when transplanted into a Parkinson’s disease model. Frontiers in Neuroscience 14, article number: 312. (10.3389/fnins.2020.00312)
2019
- Orayj, K., Lacey, A., Akbari, A., Smith, M., Pickrell, O. and Lane, E. 2019. Association between levodopa and ischemic heart disease. International Journal of Population Data Science 4(3), article number: 11. (10.23889/ijpds.v4i3.1172)
- Orayj, K. and Lane, E. 2019. Patterns and determinants of prescribing for Parkinson's Disease: A systematic literature review. Parkinson's Disease 2019, article number: 9237181. (10.1155/2019/9237181)
- Lane, E. L. 2019. L-DOPA for Parkinson's disease-a bittersweet pill. European Journal of Neuroscience 49(3), pp. 384-398. (10.1111/ejn.14119)
2018
- Elabi, O., Duskova, K., Davies, J. and Lane, E. 2018. The impact of ghrelin on the survival and efficacy of dopaminergic fetal grafts in the 6-OHDA-Lesioned rat. Neuroscience 395, pp. 13-21. (10.1016/j.neuroscience.2018.10.045)
2017
- Breger, L. S., Kienle, K., Smith, G. A., Dunnett, S. B. and Lane, E. L. 2017. Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson's disease. Brain, Behavior, and Immunity 61, pp. 155-164. (10.1016/j.bbi.2016.11.014)
2016
- Rylander Ottosson, D. and Lane, E. L. 2016. Striatal plasticity in L-DOPA- and graft-induced dyskinesia:the common link?. Frontiers in Cellular Neuroscience 10, article number: 16. (10.3389/fncel.2016.00016)
2014
- Lindgren, H. S., Demirbugen, M., Bergqvist, F., Lane, E. L. and Dunnett, S. B. 2014. The effect of additional noradrenergic and serotonergic depletion on a lateralised choice reaction time task in rats with nigral 6-OHDA lesions. Experimental Neurology 253, pp. 52-62. (10.1016/j.expneurol.2013.11.015)
2013
- Murphy, E. M., Lelos, M. J., O'Neill, M. J., Lane, E. L. and Dunnett, S. B. 2013. Long-term restorative effects of bromocriptine on operant responding in the 6-hydroxydopamine-lesioned rat. NeuroReport 24(18), pp. 1019-1024. (10.1097/WNR.0000000000000060)
- Lane, E. L., Dunnett, S. B. and Fricker, R. A. 2013. The 12th meeting of the International Society for Neural Transplantation and Restoration. NeuroReport 24(18), pp. 997-999. (10.1097/WNR.0000000000000101)
- Lelos, M. J., Lane, E. and Dunnett, S. B. 2013. What helps can also hinder: A dissociation in the acute effect of levodopa treatment on motor and cognitive functions. Movement Disorders 28(5), pp. 563-564. (10.1002/mds.25294)
- Breger, L. S., Dunnett, S. B. and Lane, E. L. 2013. Comparison of rating scales used to evaluate l-DOPA-induced dyskinesia in the 6-OHDA lesioned rat. Neurobiology of Disease 50, pp. 142-150. (10.1016/j.nbd.2012.10.013)
- Klein, A., Lane, E. L. and Dunnett, S. B. 2013. Brain repair in a unilateral rat model of Huntington's Disease: new insights into impairment and restoration of forelimb movement patterns. Cell Transplantation 22(10), pp. 1735-1751. (10.3727/096368912X657918)
2012
- Smith, G. A., Breger, L. S., Lane, E. L. and Dunnett, S. B. 2012. Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats. Neuropharmacology 63(5), pp. 818-828. (10.1016/j.neuropharm.2012.06.011)
- Smith, G. A., Dunnett, S. B. and Lane, E. L. 2012. Amphetamine-induced rotation in the transplanted hemi-parkinsonian rat - Response to pharmacological modulation. Behavioural Brain Research 232(2), pp. 411-415. (10.1016/j.bbr.2012.04.003)
- Smith, G. A., Heuer, A., Dunnett, S. B. and Lane, E. L. 2012. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: Predicting L-DOPA-induced dyskinesia. Behavioural Brain Research 226(1), pp. 281-292. (10.1016/j.bbr.2011.09.025)
- Heuer, A., Smith, G. A., Lelos, M. J., Lane, E. L. and Dunnett, S. B. 2012. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: Motor impairments identify extent of dopamine depletion at three different lesion sites. Behavioural Brain Research 228(1), pp. 30-43. (10.1016/j.bbr.2011.11.027)
- Smith, G. A. et al. 2012. L-dopa and graft-induced dyskinesia in the 6-OHDA-lesioned mouse [Abstract]. Cell Transplantation 21(4), pp. 792-792.
- Lindgren, H. S. and Lane, E. L. 2012. Rodent models of l-DOPA-induced dyskinesia. Neuromethods 61, pp. 337-351. (10.1007/978-1-61779-298-4_18)
2011
- Torres, E. M., Lane, E. L., Heuer, A., Smith, G. A., Murphy, E. M. and Dunnett, S. B. 2011. Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates. Journal of Neuroscience Methods 200(1), pp. 29-35. (10.1016/j.jneumeth.2011.06.012)
- Lane, E. L., Daly, C. S., Smith, G. A. and Dunnett, S. B. 2011. Context-driven changes in 1-DOPA-induced behaviours in the 6-OHDA lesioned rat. Neurobiology of Disease 42(1), pp. 99-107. (10.1016/j.nbd.2011.01.010)
- Smith, G. A., Lane, E. L. and Dunnett, S. B. 2011. Graft-Induced Dyskinesia in Transplanted Hemiparkinsonian Mice and Rats: A Pharmacological Manipulation [Abstract]. Cell Transplantation 20(4), pp. 585-585.
- Smith, G. A., Breger, L. S., Dunnett, S. B. and Lane, E. L. 2011. Developments in Graft-Induced Dyskinesia [Abstract]. Cell Transplantation 20(4), pp. 584-585.
- Klein, A., Lane, E. L. and Dunnett, S. B. 2011. Skilled Reaching Behavior in a Rat Model of Huntington's Disease and the Effects of Neurorestorative Therapy [Abstract]. Cell Transplantation 20(4), pp. 567-567.
- Kelly, C. et al. 2011. Medical terminations of pregnancy: A viable source of tissue for cell replacement therapy for neurodegenerative disorders. Cell Transplantation 20(4), pp. 503-513. (10.3727/096368910X546580)
- Lane, E. L. 2011. Clinical and Experimental Experiences of Graft-Induced Dyskinesia. In: Brotchie, J., Bezard, E. and Jenner, P. eds. Pathophysiology, pharmacology and biochemistry of dyskinesia. International Review of Neurobiology Vol. 98. Kidlington, Oxford: Academic Press, pp. 173-186., (10.1016/B978-0-12-381328-2.00007-9)
- Johnston, T. H. and Lane, E. L. 2011. Experimental models of L-DOPA-induced dyskinesia. In: Brotchie, J., Bezard, E. and Jenner, P. eds. Pathophysiology, Pharmacology and Biochemistry of Dyskinesia. International Review of Neurobiology Vol. 98. London: Academic Press, pp. 55-93., (10.1016/B978-0-12-381328-2.00003-1)
- Lane, E. L. and Dunnett, S. B. 2011. Preface. In: Lane, E. L. and Dunnett, S. eds. Animal Models of Movement Disorders., Vol. 1. Neuromethods Vol. 61. New York, NY: Humana Press, pp. vii-viii.
2010
- Lane, E. L. and Smith, G. A. 2010. Understanding graft-induced dyskinesia. Regenerative Medicine 5(5), pp. 787-797. (10.2217/rme.10.42)
- Lane, E. L., Björklund, A., Dunnett, S. B. and Winkler, C. 2010. Neural grafting in Parkinson's disease: unraveling the mechanisms underlying graft-induced dyskinesia. In: Björklund, A. and Cenci, M. A. eds. Recent Advances in Parkinson’s Disease: Translational and Clinical Research. Progress in Brain Research Vol. 184. London: Elsevier, pp. 295-309., (10.1016/S0079-6123(10)84015-4)
- Lane, E. L. and Dunnett, S. B. 2010. Pretreatment with dopamine agonists influences L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behavioural Brain Research 213(1), pp. 66-72. (10.1016/j.bbr.2010.04.034)
- Lane, E. L., Björklund, A., Dunnett, S. B. and Winkler, C. 2010. Neural grafting in Parkinsons disease unraveling the mechnisams underlying graft-induced dyskinesia. In: Progress in Brain Research., Vol. 184. Elsevier, pp. 295-309., (10.1016/S0079-6123(10)84015-4)
2009
- Lane, E. L., Vercammen, L., Cenci, M. A. and Brundin, P. 2009. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Experimental Neurology 219(1), pp. 355-358. (10.1016/j.expneurol.2009.04.010)
- Lane, E. L., Brundin, P. and Cenci, M. A. 2009. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiology of Disease 35(1), pp. 42-51. (10.1016/j.nbd.2009.03.014)
- Monville, C., Torres, E. M., Pekarik, V., Lane, E. L. and Dunnett, S. B. 2009. Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model. Brain Research Bulletin 78(4-5), pp. 248-253. (10.1016/j.brainresbull.2008.11.007)
2008
- Lane, E. L., Soulet, D., Vercammen, L., Cenci, M. A. and Brundin, P. 2008. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiology of Disease 32(2), pp. 220-228. (10.1016/j.nbd.2008.06.011)
- Lane, E. L., Handley, O. J., Rosser, A. E. and Dunnett, S. B. 2008. Potential cellular and regenerative approaches for the treatment of Parkinson's disease. Neuropsychiatric Disease and Treatment 4(5), pp. 835-845. (10.2147/NDT.S2013)
- Lane, E. L., Cheetham, S. and Jenner, P. 2008. Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398. Journal of Neural Transmission 115(3), pp. 423-429. (10.1007/s00702-007-0854-x)
- Lane, E. L. and Dunnett, S. B. 2008. Animal models of Parkinson's disease and L-dopa induced dyskinesia: How close are we to the clinic?. Psychopharmacology 199(3), pp. 303-312. (10.1007/s00213-007-0931-8)
- Zietlow, R., Lane, E. L., Dunnett, S. B. and Rosser, A. E. 2008. Human stem cells for CNS repair. Cell and Tissue Research 331(1), pp. 301-322. (10.1007/s00441-007-0488-1)
- Lane, E. L., Carlsson, T., Kirik, D. and Dunnett, S. B. 2008. Animal models of Parkinson's Disease. In: Conn, P. M. ed. 2008 Sourcebook of Models for Biomedical Research. Humana Press, pp. 313-322., (10.1007/978-1-59745-285-4_34)
2007
- Lane, E. L. and Dunnett, S. B. 2007. Long-term pre-administration of dopamine agonists alters L-dopa induced circling behavior in the 6-OHDA lesioned rat [Abstract]. Movement Disorders 22(S16), pp. S246. (10.1002/mds.21535)
2006
- Lane, E. L., Winkler, C., Brundin, P. and Cenci, M. A. 2006. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiology of Disease 22(2), pp. 334-345. (10.1016/j.nbd.2005.11.011)
- Lane, E. L., Cheetham, S. C. and Jenner, P. 2006. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?. Experimental Neurology 197(2), pp. 284-290. (10.1016/j.expneurol.2005.06.006)
- Lane, E. L., Winkler, C., Brundin, P. and Cenci, A. 2006. The importance of graft size in the development of graft-induced dyskinesia [Abstract]. Cell Transplantation 15(6), pp. 556-556.
2005
- Lane, E. L., Winkler, C., Mela, F., Lundblad, M., Brundin, P. and Cenci, M. A. 2005. The importance of graft size in the onset of graft-induced dyskinesia [Abstract]. Experimental Neurology 193(1), pp. 250-251. (10.1016/j.expneurol.2005.02.005)
- Lane, E. L., Cheetham, S. and Jenner, P. 2005. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D-1 and D-2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. Journal of Pharmacology and Experimental Therapeutics 312(3), pp. 1124-1131. (10.1124/jpet.104.076554)
- Lane, E. L., Cheetham, S. C. and Jenner, P. 2005. Repeated administration of the monoamine reuptake inhibitor BTS 74398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours. European Journal of Neuroscience 21(1), pp. 179-186. (10.1111/j.1460-9568.2004.03834.x)
2003
- Lane, E. L., Rose, S., Cheetham, S. and Jenner, P. 2003. Chronic administration of bts 74 398 does not induce abnormal movements in 6-OHDA lesioned rats [Abstract]. British Journal of Pharmacology 138, pp. U100.
2000
- Lane, E. L., Prow, M. R., Aspley, S., Kilpatrick, I. C. and Heal, D. J. 2000. d-fenfluramine releases 5-HT from whole blood of rats as measured by in vitro microdialysis [Abstract]. British Journal of Pharmacology 129, pp. U85.
- Lane, E. L., Prow, M. R., Butler, S. A., Aspley, S., Kilpatrick, I. C. and Heal, D. J. 2000. A simplified method for the measurement of endogenous 5-HT in rat whole blood using in vitro microdialysis [Abstract]. British Journal of Pharmacology 129, pp. U84.
Adrannau llyfrau
- Lane, E. L., Isaacs, L. and Mathur, S. 2022. More than a participant in trials of cell and gene therapy: Hearing the voices of people living with neurodegenerative diseases. In: International Review of Neurobiology., Vol. 166. ELSEVIER ACADEMIC PRESS INC, pp. 281-312., (10.1016/bs.irn.2022.09.007)
- Lane, E. L. 2011. Clinical and Experimental Experiences of Graft-Induced Dyskinesia. In: Brotchie, J., Bezard, E. and Jenner, P. eds. Pathophysiology, pharmacology and biochemistry of dyskinesia. International Review of Neurobiology Vol. 98. Kidlington, Oxford: Academic Press, pp. 173-186., (10.1016/B978-0-12-381328-2.00007-9)
- Johnston, T. H. and Lane, E. L. 2011. Experimental models of L-DOPA-induced dyskinesia. In: Brotchie, J., Bezard, E. and Jenner, P. eds. Pathophysiology, Pharmacology and Biochemistry of Dyskinesia. International Review of Neurobiology Vol. 98. London: Academic Press, pp. 55-93., (10.1016/B978-0-12-381328-2.00003-1)
- Lane, E. L. and Dunnett, S. B. 2011. Preface. In: Lane, E. L. and Dunnett, S. eds. Animal Models of Movement Disorders., Vol. 1. Neuromethods Vol. 61. New York, NY: Humana Press, pp. vii-viii.
- Lane, E. L., Björklund, A., Dunnett, S. B. and Winkler, C. 2010. Neural grafting in Parkinson's disease: unraveling the mechanisms underlying graft-induced dyskinesia. In: Björklund, A. and Cenci, M. A. eds. Recent Advances in Parkinson’s Disease: Translational and Clinical Research. Progress in Brain Research Vol. 184. London: Elsevier, pp. 295-309., (10.1016/S0079-6123(10)84015-4)
- Lane, E. L., Björklund, A., Dunnett, S. B. and Winkler, C. 2010. Neural grafting in Parkinsons disease unraveling the mechnisams underlying graft-induced dyskinesia. In: Progress in Brain Research., Vol. 184. Elsevier, pp. 295-309., (10.1016/S0079-6123(10)84015-4)
- Lane, E. L., Carlsson, T., Kirik, D. and Dunnett, S. B. 2008. Animal models of Parkinson's Disease. In: Conn, P. M. ed. 2008 Sourcebook of Models for Biomedical Research. Humana Press, pp. 313-322., (10.1007/978-1-59745-285-4_34)
Erthyglau
- Lambourne, O. A. et al. 2023. PINK1-Dependent mitophagy inhibits elevated ubiquitin phosphorylation caused by mitochondrial damage. Journal of Medicinal Chemistry 66(11), pp. 7645-7656. (10.1021/acs.jmedchem.3c00555)
- Lane, E. L. and Lelos, M. J. 2022. Defining the unknowns for cell therapies in Parkinson's disease. Disease Models and Mechanisms 15(10), article number: dmm049543. (10.1242/dmm.049543)
- Elabi, O. F. et al. 2022. Human embryonic stem cell-derived dopaminergic grafts alleviate L-DOPA induced dyskinesia. Journal of Parkinson's Disease 12(6), pp. 1881-1896. (10.3233/JPD-212920)
- Lane, E. L., Harrison, D. J., Ramos-Varas, E., Hills, R., Turner, S. and Lelos, M. J. 2022. Spontaneous graft-induced dyskinesias are independent of 5-HT neurons and levodopa priming in a model of Parkinson's disease. Movement Disorders 37(3), pp. 613-619. (10.1002/mds.28856)
- Elabi, O. F., Davies, J. S. and Lane, E. L. 2021. L-dopa-dependent effects of GLP-1R agonists on the survival of dopaminergic cells transplanted into a rat model of Parkinson disease. International Journal of Molecular Sciences 22(22), article number: 12346. (10.3390/ijms222212346)
- Orayj, K., Akbari, A., Lacey, A., Smith, M., Pickrell, O. and Lane, E. L. 2021. Factors affecting the choice of first-line therapy in Parkinson's disease patients in Wales: A population-based study. Saudi Pharmaceutical Journal 29(2), pp. 206-212. (10.1016/j.jsps.2021.01.004)
- Precious, S. V. et al. 2020. Dopaminergic progenitors derived from epiblast stem cells function similarly to primary VM-derived progenitors when transplanted into a Parkinson’s disease model. Frontiers in Neuroscience 14, article number: 312. (10.3389/fnins.2020.00312)
- Orayj, K., Lacey, A., Akbari, A., Smith, M., Pickrell, O. and Lane, E. 2019. Association between levodopa and ischemic heart disease. International Journal of Population Data Science 4(3), article number: 11. (10.23889/ijpds.v4i3.1172)
- Orayj, K. and Lane, E. 2019. Patterns and determinants of prescribing for Parkinson's Disease: A systematic literature review. Parkinson's Disease 2019, article number: 9237181. (10.1155/2019/9237181)
- Lane, E. L. 2019. L-DOPA for Parkinson's disease-a bittersweet pill. European Journal of Neuroscience 49(3), pp. 384-398. (10.1111/ejn.14119)
- Elabi, O., Duskova, K., Davies, J. and Lane, E. 2018. The impact of ghrelin on the survival and efficacy of dopaminergic fetal grafts in the 6-OHDA-Lesioned rat. Neuroscience 395, pp. 13-21. (10.1016/j.neuroscience.2018.10.045)
- Breger, L. S., Kienle, K., Smith, G. A., Dunnett, S. B. and Lane, E. L. 2017. Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson's disease. Brain, Behavior, and Immunity 61, pp. 155-164. (10.1016/j.bbi.2016.11.014)
- Rylander Ottosson, D. and Lane, E. L. 2016. Striatal plasticity in L-DOPA- and graft-induced dyskinesia:the common link?. Frontiers in Cellular Neuroscience 10, article number: 16. (10.3389/fncel.2016.00016)
- Lindgren, H. S., Demirbugen, M., Bergqvist, F., Lane, E. L. and Dunnett, S. B. 2014. The effect of additional noradrenergic and serotonergic depletion on a lateralised choice reaction time task in rats with nigral 6-OHDA lesions. Experimental Neurology 253, pp. 52-62. (10.1016/j.expneurol.2013.11.015)
- Murphy, E. M., Lelos, M. J., O'Neill, M. J., Lane, E. L. and Dunnett, S. B. 2013. Long-term restorative effects of bromocriptine on operant responding in the 6-hydroxydopamine-lesioned rat. NeuroReport 24(18), pp. 1019-1024. (10.1097/WNR.0000000000000060)
- Lane, E. L., Dunnett, S. B. and Fricker, R. A. 2013. The 12th meeting of the International Society for Neural Transplantation and Restoration. NeuroReport 24(18), pp. 997-999. (10.1097/WNR.0000000000000101)
- Lelos, M. J., Lane, E. and Dunnett, S. B. 2013. What helps can also hinder: A dissociation in the acute effect of levodopa treatment on motor and cognitive functions. Movement Disorders 28(5), pp. 563-564. (10.1002/mds.25294)
- Breger, L. S., Dunnett, S. B. and Lane, E. L. 2013. Comparison of rating scales used to evaluate l-DOPA-induced dyskinesia in the 6-OHDA lesioned rat. Neurobiology of Disease 50, pp. 142-150. (10.1016/j.nbd.2012.10.013)
- Klein, A., Lane, E. L. and Dunnett, S. B. 2013. Brain repair in a unilateral rat model of Huntington's Disease: new insights into impairment and restoration of forelimb movement patterns. Cell Transplantation 22(10), pp. 1735-1751. (10.3727/096368912X657918)
- Smith, G. A., Breger, L. S., Lane, E. L. and Dunnett, S. B. 2012. Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats. Neuropharmacology 63(5), pp. 818-828. (10.1016/j.neuropharm.2012.06.011)
- Smith, G. A., Dunnett, S. B. and Lane, E. L. 2012. Amphetamine-induced rotation in the transplanted hemi-parkinsonian rat - Response to pharmacological modulation. Behavioural Brain Research 232(2), pp. 411-415. (10.1016/j.bbr.2012.04.003)
- Smith, G. A., Heuer, A., Dunnett, S. B. and Lane, E. L. 2012. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: Predicting L-DOPA-induced dyskinesia. Behavioural Brain Research 226(1), pp. 281-292. (10.1016/j.bbr.2011.09.025)
- Heuer, A., Smith, G. A., Lelos, M. J., Lane, E. L. and Dunnett, S. B. 2012. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: Motor impairments identify extent of dopamine depletion at three different lesion sites. Behavioural Brain Research 228(1), pp. 30-43. (10.1016/j.bbr.2011.11.027)
- Smith, G. A. et al. 2012. L-dopa and graft-induced dyskinesia in the 6-OHDA-lesioned mouse [Abstract]. Cell Transplantation 21(4), pp. 792-792.
- Lindgren, H. S. and Lane, E. L. 2012. Rodent models of l-DOPA-induced dyskinesia. Neuromethods 61, pp. 337-351. (10.1007/978-1-61779-298-4_18)
- Torres, E. M., Lane, E. L., Heuer, A., Smith, G. A., Murphy, E. M. and Dunnett, S. B. 2011. Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates. Journal of Neuroscience Methods 200(1), pp. 29-35. (10.1016/j.jneumeth.2011.06.012)
- Lane, E. L., Daly, C. S., Smith, G. A. and Dunnett, S. B. 2011. Context-driven changes in 1-DOPA-induced behaviours in the 6-OHDA lesioned rat. Neurobiology of Disease 42(1), pp. 99-107. (10.1016/j.nbd.2011.01.010)
- Smith, G. A., Lane, E. L. and Dunnett, S. B. 2011. Graft-Induced Dyskinesia in Transplanted Hemiparkinsonian Mice and Rats: A Pharmacological Manipulation [Abstract]. Cell Transplantation 20(4), pp. 585-585.
- Smith, G. A., Breger, L. S., Dunnett, S. B. and Lane, E. L. 2011. Developments in Graft-Induced Dyskinesia [Abstract]. Cell Transplantation 20(4), pp. 584-585.
- Klein, A., Lane, E. L. and Dunnett, S. B. 2011. Skilled Reaching Behavior in a Rat Model of Huntington's Disease and the Effects of Neurorestorative Therapy [Abstract]. Cell Transplantation 20(4), pp. 567-567.
- Kelly, C. et al. 2011. Medical terminations of pregnancy: A viable source of tissue for cell replacement therapy for neurodegenerative disorders. Cell Transplantation 20(4), pp. 503-513. (10.3727/096368910X546580)
- Lane, E. L. and Smith, G. A. 2010. Understanding graft-induced dyskinesia. Regenerative Medicine 5(5), pp. 787-797. (10.2217/rme.10.42)
- Lane, E. L. and Dunnett, S. B. 2010. Pretreatment with dopamine agonists influences L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behavioural Brain Research 213(1), pp. 66-72. (10.1016/j.bbr.2010.04.034)
- Lane, E. L., Vercammen, L., Cenci, M. A. and Brundin, P. 2009. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Experimental Neurology 219(1), pp. 355-358. (10.1016/j.expneurol.2009.04.010)
- Lane, E. L., Brundin, P. and Cenci, M. A. 2009. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiology of Disease 35(1), pp. 42-51. (10.1016/j.nbd.2009.03.014)
- Monville, C., Torres, E. M., Pekarik, V., Lane, E. L. and Dunnett, S. B. 2009. Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model. Brain Research Bulletin 78(4-5), pp. 248-253. (10.1016/j.brainresbull.2008.11.007)
- Lane, E. L., Soulet, D., Vercammen, L., Cenci, M. A. and Brundin, P. 2008. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiology of Disease 32(2), pp. 220-228. (10.1016/j.nbd.2008.06.011)
- Lane, E. L., Handley, O. J., Rosser, A. E. and Dunnett, S. B. 2008. Potential cellular and regenerative approaches for the treatment of Parkinson's disease. Neuropsychiatric Disease and Treatment 4(5), pp. 835-845. (10.2147/NDT.S2013)
- Lane, E. L., Cheetham, S. and Jenner, P. 2008. Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398. Journal of Neural Transmission 115(3), pp. 423-429. (10.1007/s00702-007-0854-x)
- Lane, E. L. and Dunnett, S. B. 2008. Animal models of Parkinson's disease and L-dopa induced dyskinesia: How close are we to the clinic?. Psychopharmacology 199(3), pp. 303-312. (10.1007/s00213-007-0931-8)
- Zietlow, R., Lane, E. L., Dunnett, S. B. and Rosser, A. E. 2008. Human stem cells for CNS repair. Cell and Tissue Research 331(1), pp. 301-322. (10.1007/s00441-007-0488-1)
- Lane, E. L. and Dunnett, S. B. 2007. Long-term pre-administration of dopamine agonists alters L-dopa induced circling behavior in the 6-OHDA lesioned rat [Abstract]. Movement Disorders 22(S16), pp. S246. (10.1002/mds.21535)
- Lane, E. L., Winkler, C., Brundin, P. and Cenci, M. A. 2006. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiology of Disease 22(2), pp. 334-345. (10.1016/j.nbd.2005.11.011)
- Lane, E. L., Cheetham, S. C. and Jenner, P. 2006. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?. Experimental Neurology 197(2), pp. 284-290. (10.1016/j.expneurol.2005.06.006)
- Lane, E. L., Winkler, C., Brundin, P. and Cenci, A. 2006. The importance of graft size in the development of graft-induced dyskinesia [Abstract]. Cell Transplantation 15(6), pp. 556-556.
- Lane, E. L., Winkler, C., Mela, F., Lundblad, M., Brundin, P. and Cenci, M. A. 2005. The importance of graft size in the onset of graft-induced dyskinesia [Abstract]. Experimental Neurology 193(1), pp. 250-251. (10.1016/j.expneurol.2005.02.005)
- Lane, E. L., Cheetham, S. and Jenner, P. 2005. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D-1 and D-2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. Journal of Pharmacology and Experimental Therapeutics 312(3), pp. 1124-1131. (10.1124/jpet.104.076554)
- Lane, E. L., Cheetham, S. C. and Jenner, P. 2005. Repeated administration of the monoamine reuptake inhibitor BTS 74398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours. European Journal of Neuroscience 21(1), pp. 179-186. (10.1111/j.1460-9568.2004.03834.x)
- Lane, E. L., Rose, S., Cheetham, S. and Jenner, P. 2003. Chronic administration of bts 74 398 does not induce abnormal movements in 6-OHDA lesioned rats [Abstract]. British Journal of Pharmacology 138, pp. U100.
- Lane, E. L., Prow, M. R., Aspley, S., Kilpatrick, I. C. and Heal, D. J. 2000. d-fenfluramine releases 5-HT from whole blood of rats as measured by in vitro microdialysis [Abstract]. British Journal of Pharmacology 129, pp. U85.
- Lane, E. L., Prow, M. R., Butler, S. A., Aspley, S., Kilpatrick, I. C. and Heal, D. J. 2000. A simplified method for the measurement of endogenous 5-HT in rat whole blood using in vitro microdialysis [Abstract]. British Journal of Pharmacology 129, pp. U84.
Ymchwil
Research interests
- Member of the School's Pharmacology & Physiology Research Discipline
Parkinson's disease
- Mechanisms underlying dyskinesia
- Transplantation
Huntington's disease
- Mechanisms underlying chorea
Parkinson's disease and Huntington's disease are neurodegenerative movement disorders in which there is a progressive loss of specific groups of neurons in the basal ganglia circuitry. The Brain Repair Group is a 30-strong multi-disciplinary team of biomedical and clinical scientists, students and support staff, under the co-direction of 3 PI's, Dr Emma Lane in WSP, and Professors Stephen Dunnett and Anne Rosser (in the School of Bioscience).
L-dopa-induced dyskinesia
Parkinson's disease is a largely sporadic disorder which affects around 120 000 people in the UK. It is most commonly described as a motor disorder, with the cardinal features of resting tremor, rigidity, bradykinesia and postural instability. The main pathology is the loss of the melanised dopaminergic neurons of the nigrostriatal pathway and the development of protein accumulations immunopositive for the protein a-synuclein. Many of the motor symptoms of Parkinson's disease can be well controlled in the early stages with dopaminergic drugs therapies, however as the disease develop, the main treatment for Parkinson's disease, L-dopa, causes the development of abnormal involuntary movements. These can be severely debilitating and there are currently few pharmaceutical interventions to prevent or ameliorate them. Understanding the features that predispose for the development of L-dopa induced dyskinesia may increase our ability to identify patients at greater risk and avoid or minimise them with careful management of medication. Furthermore, the effects of L-dopa may go beyond motor activation and I am interested in the possible effects of long-term L-dopa administration on motor learning and habit formation using in vivo models of PD and dyskinesia.
Graft-induced dyskinesia
Not only do dyskinesia develop, but medication become less effective at treating the motor symptoms of PD as the disease progresses. Transplantation of foetal tissue into the striatum can replace the lost dopaminergic innervation and can produce remarkable improvements in motor function. However, clinical trials have identified issues that need to be carefully considered before further clinical trial of embryonic tissue or cells from alternative sources (ie stem cells) can be attempted, including reliability and reproducibility of positive results, access to sources of embryonic tissue and alternative cell types and most notably the issue of transplantation-induced side effects. Three clinical trials of transplantation with embryonic tissue have now reported the development of dyskinesia in transplanted patients unrelated to their medication, to the extent that several have required further surgical interventions to ameliorate their symptoms. The main focus of my research over the last 5 years has been in determining mechanisms and contributing risk factors for the development of post-transplantation dyskinesia in order that transplantation can proceed unhindered into the next phase of clinical trials soon to be established with the Transeuro EU FP7 award recently awarded to a consortium of several EU teams, one of which is based at Cardiff University.
Huntington's Chorea
Huntington's disease is a genetic disorder affecting around 7000 people in the UK. An elongated stretch of CAG repeats on the gene encoding the protein Huntingtin is responsible for progressive motor, cognitive and psychiatric symptoms. One of the motor symptoms can be choreiform abnormal involuntary movements often occurring in the earlier stages of disease. Our early studies are looking at how these maybe represented in animal models of Huntington's disease to increase understanding and treatment strategies targeted towards this aspect of the disease.
Addysgu
Undergraduate
- PH1124 Human body systems (Nervous Systems)
- PH3103 Autocoid, Endocrine and Immunopharmacology (binding workshop)
- PH3104 Neuropharmacology (lectures on neuroanatomy, ionotropic and metabotropic receptors, neurodegenerative diseases, pain, anxiety, and anaesthesia)
- PH4112 Pharmacy Advanced Research Specialisation (advanced essay supervision)
- PH4207 Problem solving in Pharmacy Practice (supervision of undergraduate final year projects)
Postgraduate
- Lectures on Research Students' Skills Development Programme:
- 'Preparing for the viva: Biomedical and Life Sciences'
- 'In Vivo Methods: An Introduction'
- PhD student supervision
Bywgraffiad
- 2009-onwards, Lecturer in Pharmacology, School of Pharmacy and Pharmaceutical Sciences
- 2006-2009, Post-doctoral research associate, Brain Repair Centre, Department of Neuroscience, Cardiff University
Working with Prof Stephen Dunnett and Prof Anne Rosser I continued my work on L-dopa and post-transplantation dyskinesia contributing to two successful EU FP7 grant awards. - 2004-2006, Post-doctoral research associate, Units of Neuronal Survival and Basal Ganglia Pathophysiology, Lund University, Sweden.
I spent 2 years in Sweden with the groups of Prof Patrik Brundin and Prof Angela Cenci developing, characterizing and working with a model of post-transplantation dyskinesia - 2000-2004, PhD, King's College London, UK
I had a BBSRC CASE award studentship with Prof Peter Jenner and Dr Sharon Cheetham (then Knoll Pharmaceuticals) on the potential of BTS 74398, a monoamine uptake inhibitor, as a possible anti-parkinsonian medication. - 1996-2000, Pharmacology B.Sc. Honours 1st Class with industrial placement, University College London, UK.
Specialising in neuropharmacology options and spending an industrial year at Knoll Pharmaceuticals working on the pharmacology of the anti-obesity agent sibutramine.
Anrhydeddau a dyfarniadau
Grant awards
- 2009 Wellcome Trust Biomedical Vacation Scholarship application for summer student James Davidson
- 2009-current Scanning changes in functional brain activity associated with dyskinesia in parkinsonian rats. Parkinson's Disease Society Innovations grant, £15,000 (PI with Stephen Paisey and Stephen Dunnett)
- 2008-2009 Wellcome Trust Value In People Award.
- 2006-2009 Does the storage of embryonic tissue prior to transplantation affect immune responses to the graft and the development of graft induced dyskinesias? Parkinsonfonden, 100,000 SEK (PI)
- 2006-2010 Understanding and eliminating the dyskinetic effects of nigral grafts. (Co-PI with Stephen Dunnett and Christelle Monville,)
- 2005-2007 Pharmacological investigation into amphetamine induced dyskinesia. Parkinsonfonden, 100,000 SEK (PI)
Aelodaethau proffesiynol
- 2009-current, Society for Neuroscience
- 2008-current, Fellow of the Higher Education Academy
- 2004-current, NECTAR (Network of European CNS Transplantation and Restoration)
Board member from 2009 - 2010 - President-elect of NECTAR
- 2000-current, British Neuroscience Association